The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain
- 15 January 2007
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (2), 385-389
- https://doi.org/10.1016/j.bmcl.2006.10.041
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Lumiracoxib, a highly selective COX-2 inhibitorExpert Review of Clinical Immunology, 2005
- Gastrointestinal Effects of Selective and Non-Selective Non-Steroidal Anti- Inflammatory DrugsCurrent Pharmaceutical Design, 2005
- The Role of COX-2 in Acute Pain and the Use of Selective COX-2 Inhibitors for Acute Pain ReliefCurrent Pharmaceutical Design, 2005
- Reduced Pain Hypersensitivity and Inflammation in Mice Lacking Microsomal Prostaglandin E Synthase-1Published by Elsevier BV ,2004
- Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthaseProceedings of the National Academy of Sciences of the United States of America, 2003
- Microsomal Prostaglandin E Synthase-1 Is a Major Terminal Synthase That Is Selectively Up-Regulated During Cyclooxygenase-2-Dependent Prostaglandin E2 Production in the Rat Adjuvant-Induced Arthritis ModelPublished by The American Association of Immunologists ,2003
- The role of COX-2 inhibitors in pain modulation.Drugs, 2003
- A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.Drugs, 2003
- Prostaglandin E synthaseProstaglandins & Other Lipid Mediators, 2002
- Gastrointestinal side effects of NSAIDs – pharmacoeconomic implicationsExpert Opinion on Pharmacotherapy, 2002